abstract |
The invention relates to novel substituted alpha , beta -anellated butyrolactones, to methods for producing them and to their use for preventing and/or treating diseases caused by a hyperfunction or hypofunction of the glutamatergic system, especially cerebral ischaemia, cranial/cerebral trauma, pain or CNS-induced cramps. |